ArticlePloS one2025
Integrative molecular network analysis of genetic risk factors to infer biomarkers and therapeutic targets for rheumatoid arthritis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding the interplay between genetic risk factors and molecular pathways in rheumatoid arthritis (RA) is essential for developing effective treatments. This study aims to utilize genetic risk factors of RA and identify their key pathways and potential therapeutic targets through an integrated multi-omics approach.
methodsWe developed a computational pipeline to construct a knowledge graph that combines genetic risk factor molecular networks with multi-omics enrichment analysis to estimate potential therapeutic target for RA. Genetic risk factors were extracted from the literature, curated, and annotated. Molecular interaction networks were constructed based on these genetic risk factors and their neighboring proteins. Enrichment analysis was performed to identify significantly impacted biological processes and pathways. Multi-omics knowledge graph was used to prioritize candidates potential therapeutic target for RA.
resultsOur analysis identified 35 significant genes associated with RA as potential therapeutic targets and biomarkers, categorized into three pathways: Cytokine Regulation and Production, Hematopoietic or Lymphoid Organ Development, and Myeloid Cell Differentiation. Among these, 25 genes were classified as risk genes, while 10 were neighboring genes. We identified nine novel risk proteins (RELA, ETS1, NFATC1, BATF, LCK, PIK3R1, PRKCB, RASGRP1,and FYN) as potential therapeutic targets for RA and they significantly contribute in the disease pathogenesis.
conclusionThis study provides a comprehensive integrative molecular network and knowledge graph analysis of genetic risk factors in RA, offering a solid framework for integrating multi-omics data in RA research. These findings may contribute to more accurate clinical decision-making and the development of targeted treatment regimens. Additionally, this study highlights the importance of inferring hidden relationships across networks based on disease associations and functional similarities, further enhancing our understanding of RA pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.